Heparan sulphate, its derivatives and analogues share structural characteristics that can be exploited, particularly in inhibiting microbial attachment

Brazilian Journal of Medical and Biological Research

Volumn 45, Issue 5, 2012, Pages 386-391

  Rudd, T R ^a   Hughes, A ^b   Holman, J ^b   De Oliveira Ferreira, E ^c   Cavalcante Pilotto Domingues, R M ^c   Yates, E A ^b  

^a Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

^c FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

Biosynthesis; Heparan sulfate; Microbial attachment; Structure function

Indexed keywords

ADHESIN; ANTIINFECTIVE AGENT; CARBOHYDRATE DERIVATIVE; CATHELICIDIN; CHEMOKINE; CHONDROITIN SULFATE; CYTOKINE; DEFENSIN; GAG PROTEIN; GLYCOPROTEIN; GROWTH FACTOR; HEPARAN SULFATE; HEPARIN; PROTEINASE; PROTEOGLYCAN; SYNDECAN 1; SYNDECAN 4; VIRULENCE FACTOR;

ARTICLE; BACTERIAL INFECTION; BACTERIUM ADHERENCE; BORRELIA BURGDORFERI; CARBOHYDRATE ANALYSIS; CARBOHYDRATE SYNTHESIS; CHAGAS DISEASE; DENGUE VIRUS; EXTRACELLULAR MATRIX; HERPES SIMPLEX VIRUS 1; HERPES SIMPLEX VIRUS 2; INTRACELLULAR SIGNALING; LEPTOSPIROSIS; MALARIA; MICROBIAL ADHESION; MICROBIOLOGICAL PHENOMENA AND FUNCTIONS; NEISSERIA GONORRHOEAE; NONHUMAN; PARASITOSIS; PATHOGENESIS; PLASMODIUM FALCIPARUM; PLASMODIUM VIVAX; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SEXUALLY TRANSMITTED DISEASE; STAPHYLOCOCCUS AUREUS; STRUCTURE ACTIVITY RELATION; TRYPANOSOMA CRUZI; VIRUS ATTACHMENT; VIRUS INFECTION;

BACTERIA (MICROORGANISMS);

EID: 84861121953     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2012007500048     Document Type: Article

References (44)

1. Sampaio LO, Tersariol ILS, Lopes CC, Bouças RI, Nascimento FD, Rocha HAO, et al. Heparins and heparan sulfates. Structure, distribution and protein interactions. In: Verli H (Editor), Insights into carbohydrate structure and biological function. Kerala: Transworld Research Network; 2006, p 51-61.
2. Ori A, Free P, Courty J, Wilkinson MC, Fernig DG. Identification of heparin-binding sites in proteins by selective labeling. Mol Cell Proteomics 2009; 8: 2256-2265.
3. Ori A, Wilkinson MC, Fernig DG. A systems biology approach for the investigation of the heparin/heparan sulfate interactome. J Biol Chem 2011: 286: 19892-19904.
4. Choay J, Petitou M, Lormeau JC, Sinay P, Casu B, Gatti G. Structure-activity relationship in heparin: a synthetic pentasaccharide with high affinity for antithrombin IIl and eliciting high anti-factor Xa activity. Biochem Biophys Res Commun 1983; 116: 492-499.
5. Atha DH, Lormeau JC, Petitou M, Rosenberg RD, Choay J. Contribution of monosaccharide residues in heparin binding to antithrombin Ill. Biochemistry 1985; 24: 6723-6729.
6. Thunberg L, Backstrom G, Lindahl U. Further characterization of the antithrombin-binding sequence in heparin. Carbohydr Res 1982; 100: 393-410.
7. Rudd TR, Uniewicz KA, Ori A, Guimond SE, Skidmore MA, Gaudesi D, et al. Comparable stabilisation, structural changes and activities can be induced in FGF by a variety of HS and non-GAG analogues: implications for sequence-activity relationships. Org Biomol Chem 2010: 8: 5390-5397.
8. Yates EA, Guimond SE, Turnbull JE. Highly diverse heparan sulfate analogue libraries: providing access to expanded areas of sequence space for bioactivity screening. J Med Chem 2004; 47: 277-280.
9. Uniewicz KA, Ori A, Xu R, Ahmed Y, Wilkinson MC, Fernig DG, et al. Differential scanning fluorimetry measurement of protein stability changes upon binding to glycosaminoglycans: a screening test for binding specificity. Anal Chem 2010; 82: 3796-3802
10. Solari V, Jesudason EC, Turnbull JE, Yates EA. Determining the anti-coagulant-independent anti-cancer effects of heparin. Br J Cancer 2010: 103: 593-594.
11. Bartlett AH, Park PW. Proteoglycans in host-pathogen interactions: molecular mechanisms and therapeutic implications. Expert Rev Mol Med 2010; 12: e5.
12. Kitov PI, Bundle DR. On the nature of the multivalency effect: a thermodynamic model. J Am Chem Soc 2003; 125: 16271-16284.
13. Tumova S, Woods A, Couchman JR. Heparan sulfate chains from glypican and syndecans bind the Hep II domain of fibronectin similarly despite minor structural differences. J Biol Chem 2000; 275: 9410-9417.
14. Filmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest 2001; 108: 497-501.
15. Spillmann D. Heparan sulfate: anchor for viral intruders? Biochimie 2001: 83: 811-817.
16. Germi R, Crance JM, Garin D, Guimet J, Lortat-Jacob H, Ruigrok RW, et al. Heparan sulfate-mediated binding of infectious dengue virus type 2 and yellow fever virus. Virology 2002: 292: 162-168
17. Dalrymple N, Mackow ER. Productive dengue virus infection of human endothelial cells is directed by heparan sulfatecontaining proteoglycan receptors. J Virol 2011; 85: 9478-9485.
18. O'Donnell CD, Tiwari V, Oh MJ, Shukla D. A role for heparan sulfate 3-O-sulfotransferase isoform 2 in herpes simplex virus type 1 entry and spread. Virology 2006; 346: 452-459.
19. Barocchi MA, Ko AI, Reis MG, McDonald KL, Riley LW. Rapid translocation of polarized MDCK cell monolayers by Leptospira interrogans, an invasive but nonintracellular pathogen. Infect Immun 2002; 70: 6926-6932.
20. Breiner DD, Fahey M, Salvador R, Novakova J, Coburn J. Leptospira interrogans binds to human cell surface receptors including proteoglycans. Infect Immun 2009; 77: 5528-5536
21. Leong JM, Morrissey PE, Ortega-Barria E, Pereira ME, Coburn J. Hemagglutination and proteoglycan binding by the Lyme disease spirochete, Borrelia burgdorferi. Infect Immun 1995; 63: 874-883.
22. Patti JM, Hook M. Microbial adhesins recognizing extracellular matrix macromolecules. Curr Opin Cell Biol 1994; 6: 752-758.
23. Fischer JR, LeBlanc KT, Leong JM. Fibronectin binding protein BBK32 of the Lyme disease spirochete promotes bacterial attachment to glycosaminoglycans. Infect Immun 2006: 74: 435-441.
24. Ballard SA, Williamson M, Adler B, Vinh T, Faine S. Interactions of virulent and avirulent leptospires with primary cultures of renal epithelial cells. J Med Microbiol 1986; 21: 59-67.
25. Choy HA, Kelley MM, Chen TL, Moller AK, Matsunaga J, Haake DA. Physiological osmotic induction of Leptospira interrogans adhesion: LigA and LigB bind extracellular matrix proteins and fibrinogen. Infect Immun 2007; 75: 2441-2450.
26. Carvalho E, Barbosa AS, Gomez RM, Cianciarullo AM, Hauk P, Abreu PA, et al. Leptospiral TIyC is an extracellular matrixbinding protein and does not present hemolysin activity. FEBS Lett 2009; 583: 1381-1385
27. Freissler E, Meyer auf der HA, David G, Meyer TF, Dehio C. Syndecan-1 and syndecan-4 can mediate the invasion of OpaHSPG-expressing Neisseria gonorrhoeae into epithelial cells. Cell Microbiol 2000; 2: 69-82.
28. van Putten JP, Duensing TD, Cole RL. Entry of OpaA+ gonococci into HEp-2 cells requires concerted action of glycosaminoglycans, fibronectin and integrin receptors. Mol Microbiol 1998; 29: 369-379.
29. Fernandes AB, Neira I, Ferreira AT, Mortara RA. Cell invasion by Trypanosoma cruzi amastigotes of distinct infectivities: studies on signaling pathways. Parasitol Res 2006; 100: 59-68.
30. Yoshida N, Cortez M. Trypanosoma cruzi: parasite and host cell signaling during the invasion process. Subcell Biochem 2008; 47: 89-91
31. Ley V, Andrews NW, Robbins ES, Nussenzweig V. Amastigotes of Trypanosoma cruzi sustain an infective cycle in mammalian cells. J Exp Med 1988; 168: 649-659.
32. Dreyfuss JL, Regatieri CV, Jarrouge TR, Cavalheiro RP, Sampaio LO, Nader HB. Heparan sulfate proteoglycans: structure, protein interactions and cell signaling. An Acad Bras Cienc 2009: 81: 409-429.
33. Oliveira FO Jr, Alves CR, Calvet CM, Toma L, Boucas RI, Nader HB, et al. Trypanosoma cruzi heparin-binding proteins and the nature of the host cell heparan sulfate-binding domain. Microb Pathog 2008; 44: 329-338.
34. Bambino-Medieros R, Oliveira FO, Calvet CM, Vicente D, Toma L, Krieger MA, et al. Involvement of host cell heparan sulfate proteoglycan in Trypanosoma cruzi amastigote attachment and invasion. Parasitol 2011; 138: 593-601.
35. Lai Y, Gallo RL. AMPed up immunity: how antimicrobial peptides have multiple roles in immune defense. Trends Immunol 2009: 30: 131-141.
36. Park PW, Foster TJ, Nishi E, Duncan SJ, Klagsbrun M, Chen Y. Activation of syndecan-1 ectodomain shedding by Staphylococcus aureus alpha-toxin and beta-toxin. J Biol Chem 2004: 279: 251-258.
37. Romanos MT, Andrada-Serpa MJ, Mourão PA, YoneshigueValentin Y, Costa SS, Pereira MS, et al. A sulphated fucan from the Laminaria abyssalis inhibits the human T cell lymphotropic virus type 1-induced syncytium formation in HeLa cells. Antivir Chem Chemother 2002; 13: 219-221.
38. Adams Y, Smith SL, Schwartz-Albiez R, Andrews KT. Carrageenans inhibit the in vitro growth of Plasmodium falciparum and cytoadhesion to CD36. Parasitol Res 2005; 97: 290-294.
39. Buck CB, Thompson CD, Roberts JN, Muller M, Lowy DR, Schiller JT. Carrageenan is a potent inhibitor of papillomavirus infection. PLoS Pathoa 2006: 2: e69.
40. Talarico LB, Damonte EB. Interference in dengue virus adsorption and uncoating by carrageenans. Virology 2007; 363: 473-485.
41. Skidmore MA, Dumax-Vorzet AF, Guimond SE, Rudd TR, Edwards EA, Turnbull JE, et al. Disruption of rosetting in Plasmodium falciparum malaria with chemically modified heparin and low molecular weight derivatives possessing reduced anticoagulant and other serine protease inhibition activities. J Med Chem 2008; 51: 1453-1458.
42. Rusnati M, Urbinati C. Polysulfated/sulfonated compounds for the development of drugs at the crossroad of viral infection and oncogenesis. Curr Pharm Des 2009; 15: 2946-2957.
43. Kyriacou HM, Steen KE, Raza A, Arman M, Warimwe G, Bull PC, et al. In vitro inhibition of Plasmodium falciparum rosette formation by Curdlan sulfate. Antimicrob Agents Chemother 2007; 51: 1321-1326.
44. Carvalho BO, Lopes SC, Nogueira PA, Orlandi PP, Bargieri DY, Blanco YC, et al. On the cytoadhesion of Plasmodium vivax-infected erythrocytes. J Infect Dis 2010; 202: 638-647.